- Previous Close
1.7960 - Open
1.7900 - Bid 1.7300 x --
- Ask 1.7360 x --
- Day's Range
1.6800 - 1.7900 - 52 Week Range
1.0600 - 3.9900 - Volume
108,695 - Avg. Volume
411,788 - Market Cap (intraday)
194.724M - Beta (5Y Monthly) -0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 9, 1996
- 1y Target Est
18.08
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
www.medivir.comRecent News: MVIR.ST
View More
Performance Overview: MVIR.ST
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MVIR.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MVIR.ST
View MoreValuation Measures
Market Cap
201.45M
Enterprise Value
149.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
58.79
Price/Book (mrq)
1.74
Enterprise Value/Revenue
43.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.76%
Return on Equity (ttm)
-73.97%
Revenue (ttm)
3.48M
Net Income Avi to Common (ttm)
-123.32M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
62.53M
Total Debt/Equity (mrq)
9.58%
Levered Free Cash Flow (ttm)
-81.41M